PHAT - NASDAQ

Phathom Pharmaceuticals, Inc.

PHAT·NASDAQ

$9.94

+3.0%

HealthcareBiotechnology

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$792.77M

EPS-3.0300

P/E Ratio-3.28

Earnings Date08/06/2026

phat

Total Debt

Last Annual Value

2.71M

3-Year CAGR

-70%

5-Year CAGR

-44%

10-Year CAGR

Adjust for Inflation

Phathom Pharmaceuticals, Inc. Competitors Analysis of Total Debt

PHAT · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	2.71M	-73.1%	-50.5%	N/A
AnaptysBio, Inc. NASDAQ:ANAB	14.11M	-7.5%	-7.6%	0.2%
Xencor, Inc. NASDAQ:XNCR	187.75M	31.0%	40.8%	N/A
Nurix Therapeutics, Inc. NASDAQ:NRIX	55.73M	22.1%	33.7%	N/A
UroGen Pharma Ltd. NASDAQ:URGN	128.33M	8.9%	217.5%	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	78.86M	-8.8%	-6.6%	N/A
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	2.77M	240.5%	137.0%	N/A
Septerna, Inc. NASDAQ:SEPN	23.62M	23.4%	N/A	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	1.71M	37.6%	N/A	N/A
Kodiak Sciences Inc. NASDAQ:KOD	59.18M	-31.2%	-19.9%	78.0%

Phathom Pharmaceuticals, Inc. Fair Value Envelope

PHAT · NASDAQ

Our analysis suggests that PHAT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.94, this represents a potential HIDDEN relative to our calculated worth for Phathom Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $9.94

Related Guides

Blog Categories

Continue your PHAT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.